NCT01033396View on ClinicalTrials.gov

The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Allergic Rhinitis
Interventions
DRUG

PF-03654764

PF-03654764 single dose 5 mg

DRUG

Allegra

Fexofenadine single dose 60 mg

DRUG

PF-03654764

PF-03654764 single dose 5 mg

DRUG

Allegra-D

Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose

DRUG

Placebo

Placebo single dose

Trial Locations (1)

K7L 2V7

Pfizer Investigational Site, Kingston

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01033396 - The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis | Biotech Hunter | Biotech Hunter